A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report.”
Opinion | Vaccine Research and Combating the Anti-Science Movement Go Hand in Hand
Hotez is a professor of pediatrics and molecular virology and microbiology. It might not be intuitive why, as an MD-PhD laboratory investigator who develops vaccines
September 20, 2023